Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
Nourseothricin sulfate resistance in E. coli can make resistant bacteria susceptible by removing their outer membrane resistance. Nourseothricin sulfate can enter the cell through porin pores and cross the outer membrane. Previous research had demonstrated that nourseothricin sulfate may open up specific channels in the outer membrane that allowed the drug to enter the cell wall. Nonetheless, there are signs that resistant strains with inactivated Nourseothricin sulfate acetyltransferase may have an extra defense mechanism in the form of a weakened outer membrane.
|
---|---|
ln Vivo |
Nephrotoxicity symptoms may appear after the administration of nourseothricin sulfate, as the kidneys are the organs that preferentially eliminate the medication. Using renal cortical slices, tests were conducted under different experimental settings to assess the renal processing of Nourseothricin sulfate. Nourseothricin has no effect on the renal tubular transport system of the organic anion (para-aminohippurate, PAH) following in vivo administration. Renal cortical sections had a significant concentration of nourseothricin sulfate accumulation. Nourseothricin sulfate buildup was unaffected by probenecid, trihydroxyaminomethane, or simultaneous administration of PAH or nitrogen atmosphere, in contrast to PAH accumulation. There are no age-related variations in the buildup of Nourseothricin sulfate [4].
|
References |
Molecular Formula |
C50H94N20O22S
|
---|---|
Molecular Weight |
1359.47
|
Exact Mass |
502.249
|
CAS # |
96736-11-7
|
PubChem CID |
131668562
|
Appearance |
White to off-white solid powder
|
Density |
1.9±0.1 g/cm3
|
Index of Refraction |
1.790
|
LogP |
-5.12
|
Hydrogen Bond Donor Count |
12
|
Hydrogen Bond Acceptor Count |
15
|
Rotatable Bond Count |
11
|
Heavy Atom Count |
40
|
Complexity |
897
|
Defined Atom Stereocenter Count |
9
|
SMILES |
C1[C@H]([C@@H]2[C@@H](C(=O)N1)N=C(N2)N[C@H]3[C@@H]([C@@H]([C@H]([C@H](O3)CO)OC(=O)N)O)NC(=O)C[C@H](CCCN)N)O.OS(=O)(=O)O
|
InChi Key |
UDVWKDBCMFLRQW-TWRCRAKCSA-N
|
InChi Code |
InChI=1S/C19H34N8O8.H2O4S/c20-3-1-2-7(21)4-10(30)24-13-14(31)15(35-18(22)33)9(6-28)34-17(13)27-19-25-11-8(29)5-23-16(32)12(11)26-19;1-5(2,3)4/h7-9,11-15,17,28-29,31H,1-6,20-21H2,(H2,22,33)(H,23,32)(H,24,30)(H2,25,26,27);(H2,1,2,3,4)/t7-,8+,9+,11+,12-,13+,14-,15-,17+;/m0./s1
|
Chemical Name |
[(2R,3R,4S,5R,6R)-6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3S)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate;sulfuric acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : 250 mg/mL (183.90 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (73.56 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.7356 mL | 3.6779 mL | 7.3558 mL | |
5 mM | 0.1471 mL | 0.7356 mL | 1.4712 mL | |
10 mM | 0.0736 mL | 0.3678 mL | 0.7356 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.